AAREYDRUGS
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) Stock Analysis
Aarey Drugs & Pharmaceuticals Limited is an Indian pharmaceutical company engaged in manufacturing and marketing formulations and bulk drugs. It supplies generic medicines and active pharmaceutical ingredients to domestic and export markets. The company operates in the competitive Indian pharma SME segment. It is listed on BSE and manufactures from facilities in India.
Healthcare › Drug Manufacturers - Specialty & Generic
₹112.90
+8.48% 1W | +20.00% 52W
Market Cap
360 CR
P/E Ratio
76.8
52W High
₹113.5
52W Low
₹50.3
Div. Yield
0%
Beta
1.2
50 DMA
₹94.1
200 DMA
₹80.1
Profit Margin
0.9%
Inst. Own.
1.8%
⚠️ BREAKDOWN
🔥 APPROACHING RESISTANCE
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 50.96 | 57.83 | 76.48 | 210.35 | 126.91 | 105.14 | 133.79 | 108.10 | 102.21 | 84.16 | 96.43 | 189.47 | 44.63 |
| Expenses | 49.62 | 55.99 | 73.78 | 211.79 | 125.73 | 101.42 | 131.59 | 112.31 | 100.50 | 81.52 | 97.94 | 185.13 | 43.31 |
| Operating Profit | 1.34 | 1.84 | 2.70 | -1.44 | 1.18 | 3.72 | 2.20 | -4.21 | 1.71 | 2.64 | -1.51 | 4.34 | 1.32 |
| OPM % | 2.63% | 3.18% | 3.53% | -0.68% | 0.93% | 3.54% | 1.64% | -3.89% | 1.67% | 3.14% | -1.57% | 2.29% | 2.96% |
| Other Income | 0.70 | 0.84 | 0.29 | 5.14 | 1.58 | 0.02 | 0.68 | 7.54 | 1.55 | 0.79 | 4.18 | -0.43 | 1.72 |
| Interest | 0.42 | 0.41 | 0.47 | 0.40 | 0.96 | 0.49 | 0.58 | 1.30 | 1.04 | 1.26 | 0.92 | 1.78 | 1.67 |
| Depreciation | 0.89 | 1.27 | 1.06 | 1.15 | 0.47 | 1.51 | 0.90 | 0.41 | 0.49 | 0.69 | 0.83 | 0.85 | 0.85 |
| Profit before tax | 0.73 | 1.00 | 1.46 | 2.15 | 1.33 | 1.74 | 1.40 | 1.62 | 1.73 | 1.48 | 0.92 | 1.28 | 0.52 |
| Tax % | 0.00% | -22.00% | 30.14% | -0.47% | 6.77% | 8.62% | 48.57% | 71.60% | 20.81% | 31.08% | 38.04% | -21.88% | -98.08% |
| Net Profit | 0.72 | 1.23 | 1.02 | 2.15 | 1.24 | 1.60 | 0.72 | 0.47 | 1.37 | 1.02 | 0.57 | 1.56 | 1.02 |
| EPS in Rs | 0.28 | 0.48 | 0.40 | 0.77 | 0.44 | 0.57 | 0.25 | 0.17 | 0.48 | 0.36 | 0.20 | 0.55 | 0.36 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 213 | 246 | 396 | 349 | 354 | 298 | 348 | 493 | 419 | 396 | 474 | 472 | 415 |
| Expenses | 212 | 245 | 386 | 342 | 347 | 294 | 344 | 481 | 411 | 391 | 471 | 465 | 408 |
| Operating Profit | 1 | 1 | 10 | 8 | 8 | 3 | 5 | 11 | 8 | 4 | 3 | 7 | 7 |
| OPM % | 0.6% | 0.4% | 2.4% | 2.2% | 2.2% | 1.1% | 1.3% | 2.3% | 1.8% | 1.1% | 0.6% | 1.5% | 1.6% |
| Other Income | 3 | 3 | 3 | 3 | 4 | 7 | 7 | 3 | 3 | 7 | 10 | 6 | 6 |
| Interest | 1 | 2 | 4 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 5 | 6 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 |
| Profit before tax | 1 | 2 | 8 | 8 | 9 | 7 | 8 | 10 | 6 | 5 | 6 | 5 | 4 |
| Tax % | 23% | 29% | 31% | 25% | 27% | 20% | 21% | 35% | 37% | 12% | 34% | 27% | |
| Net Profit | 1 | 1 | 5 | 6 | 7 | 6 | 7 | 7 | 4 | 5 | 4 | 4 | 4 |
| EPS in Rs | 0.65 | 0.77 | 3.02 | 2.64 | 2.80 | 2.48 | 2.78 | 2.58 | 1.49 | 1.67 | 1.42 | 1.40 | 1.47 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 4.0% | 6.0% | 7.0% |
| Profit CAGR | 2.0% | -9.0% | 12.0% |
Shareholding Pattern
Promoters44.80%
FIIs1.13%
Public54.07%
Promoters39.05%
FIIs3.86%
Public57.09%
Promoters37.71%
FIIs4.18%
DIIs1.62%
Public56.49%
Promoters37.71%
FIIs4.81%
DIIs1.62%
Public55.87%
Promoters42.79%
FIIs4.41%
DIIs1.49%
Public51.31%
Promoters50.05%
FIIs3.92%
Public46.04%
Promoters45.28%
FIIs3.40%
Public51.31%
Promoters44.80%
FIIs2.34%
Public52.86%
Promoters37.71%
FIIs4.18%
DIIs1.62%
Public56.49%
Promoters42.79%
FIIs4.41%
DIIs1.49%
Public51.31%
AAREYDRUGS
Holdings Analysis
Key strengths & risk signals
58
Overall
36
Fundamental
81
Technical
Risks (2)
OVERVALUED! PEG of 45.18 means expensive relative to growth rate.
OVERBOUGHT! RSI at 70.7 - caution, may pull back.
Strengths (4)
MODERATE STABILITY! 2 revenue dips in history. Acceptable but monitor closely.
BULLISH TREND! 50-day average (94.1) is above 200-day average (80.1) - positive signal.
BREAKOUT! Stock has broken above resistance levels with momentum.
STRONG! Trading at 99.1% of 52W range - near yearly highs.
Fundamental & Technical Analysis
58Overall
36Fundamental
81Technical
Fundamental Breakdown
Growth Quality
10/30
Revenue CAGR: 4.5% (SLOW, 5/15). Profit CAGR: 1.7% (SLOW, 5/15).
Profit Margin
2/10
LOW MARGIN! 0.9% profit margin - thin profits.
PEG Valuation
0/10
OVERVALUED! PEG of 45.18 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 46.03% public ownership - higher volatility risk.
Stability Index
6/10
MODERATE STABILITY! 2 revenue dips in history. Acceptable but monitor closely.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (94.1) is above 200-day average (80.1) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (112.9) is above both moving averages.
Trend Pattern
20/20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance
6/10
POSITIVE YEAR! Stock gained 20.0% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 24 up days, 6 down days. Avg volume on up days: 243,636 vs down days: 204,499. Ratio: 1.19x
RSI
2/5
OVERBOUGHT! RSI at 70.7 - caution, may pull back.
52W Range
5/5
STRONG! Trading at 99.1% of 52W range - near yearly highs.
Momentum
5/5
STRONG MOMENTUM! Price has grown across all timeframes - up 8.5% (1 week), 13.0% (1 month), 50.8% (3 months). Momentum is accelerating.
Beta
3/5
ABOVE MARKET! Beta of 1.20 - more volatile than market.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AAREYDRUGS | ₹112.90 | 76.8 | 0.9% | 4.5% | 1.7% | +20.0% | 58 | BREAKOUT | -28.6% | -37.5% | -56.4% | -76.5% |
| MEDICAMEQ | ₹284.40 | 38.4 | 4.7% | 12.0% | -13.4% | -6.8% | 57 | CONSOLIDATING DOWN | -4.5% | -46.2% | +11.4% | -21.0% |
| AMBALALSA | ₹37.80 | 22.2 | 6.6% | 5.8% | 15.9% | +16.7% | 63 | BOUNCE FROM SUPPORT | -51.2% | -38.5% | -7.2% | -33.4% |
| ALBERTDAVD | ₹831.00 | 21 | 6.2% | -1.1% | – | +1.5% | 51 | APPROACHING SUPPORT | +305.1% | -249.5% | +43.5% | +17.9% |
| NECLIFE | ₹10.50 | 30.1 | – | – | – | -24.6% | 44 | APPROACHING SUPPORT | -75.6% | -77.3% | – | – |
| BROOKS | ₹67.60 | 15 | 15.9% | 11.0% | – | -42.5% | 62 | BREAKOUT | -118.8% | -220.0% | -9.8% | +13.9% |
| MEDICO | ₹22.00 | 13.2 | 5.8% | 13.8% | 21.9% | -54.4% | 58 | BOUNCE FROM SUPPORT | +38.9% | -57.6% | +81.2% | +22.2% |
| NATCAPSUQ | ₹160.40 | – | -8.1% | 3.6% | – | -27.7% | 37 | BREAKDOWN | +1.8% | +14.0% | +7.7% | -16.8% |
Data from TradeAlone · Updated daily
No news tagged for AAREYDRUGS yet.
